Effect of concomitant oral chronic dipyridamole therapy on inflammatory cytokines in heart failure patients

Clinical Laboratory

Volumn 59, Issue 7-8, 2013, Pages 843-849

  Del Ry, Silvia ^a   Morales, Maria Aurora ^a   Scali, Maria Chiara ^b   Tafi, Alessandro ^b   Giustarini, Carlo ^b   Posteraro, Federico ^b   Ambrosini, Vittorio ^b   Agrusta, Marco ^b   Picano, Eugenio ^a   Sicari, Rosa ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b Riabilitazione Auxilium Vitae ^*  (Italy)

Author keywords

Adenosine; Cytokines; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEART FAILURE; HUMAN; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT DURATION;

CYTOKINES; DIPYRIDAMOLE; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84883227400     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.120816     Document Type: Article

References (34)

1. Mann DL. Inflammatory mediators and the failing heart: past, present and the foreseeable future. Circulation Res 2002;91:988-98. (Pubitemid 35416635)
2. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41. (Pubitemid 20225044)
3. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6. (Pubitemid 26117714)
4. Kitakaze M, Minamino T, Node K, et al. Elevation of plasma adenosine levels may attenuate the severity of chronic heart failure. Cardiovasc Drugs Ther 1998;12:307-9.
5. Sanada S, Asanuma H, Koretsune Y, et al. Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open randomized study. Hypertens Res 2007;30:913-9. (Pubitemid 350120968)
6. Akhtar M, Ordovas K, Martin A, Higgins CB, Michaels AD. Effect of chronic sustained release dipyridamole on myocardial blood flow and left ventricular function in patients with ischemic cardiomyopathy. Congest Heart Fail 2007;13:130-5.
7. Sacco RL, Diener HC, Yusuf S, et al. PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51.
8. Haskó G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008;83:447-55. (Pubitemid 351966849)
9. Picano E, Morales MA, Del Ry S, Sicari R. Innate inflammation in myocardial perfusion and its implication for heart failure. Ann of the New York Academy of Sciences 2010.
10. Del Ry S, Giannessi D, Maltinti M, et al. Increased plasma levels of osteopontin are associated with activation of the renin-aldosterone system and with myocardial and coronary microvascular damage in dilated cardiomyopathy. Cytokine 2010;49:325-30.
11. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino A, Clerico A. Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin Chem 2003;49:1552-4. (Pubitemid 37011754)
12. Del Ry S, Cabiati M, Stefano T, et al. Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients. Regulatory Peptides 2010 Aug 26.(in press)
13. Pilo A, Zucchelli GC, Malvano R, Masini S. Main features of computer algorithms for RIA data reduction. Comparison of some different approaches for the interpolation of dose-response curve. J Nucl Med All Sci 1982;26:235-48. (Pubitemid 13194445)
14. Dickstein K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. Reply. Eur Heart J 2008 Dec 24.
15. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA. NHLBI Working Group on the Translation of Therapies for Protecting the Heart from Ischemia. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004;95:125-34.
16. Funakoshi H, Zacharia LC, Tang Z, et al. A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation 2007;115:2307-15. (Pubitemid 46685899)
17. Torry RJ, O'Brien DM, Connell PM, Tomanek RJ. Dipyridamole-induced capillary growth in normal and hypertrophic hearts. Am J Physiol 1992;262:H980-6.
18. Epperson SA, Brunton LL, Ramirez-Sanchez I, Villarreal F. Adenosine receptors and second messenger signaling pathways in rat cardiac fibroblasts. Am J Physiol Cell Physiol 2009;296:C1171-7.
19. Simonis G, Wiedemann S, Joachim D, Weinbrenner C, Marquetant R, Strasser RH. Stimulation of adenosine A2b receptors blocks apoptosis in the non-infarcted myocardium even when administered after the onset of infarction. Mol Cell Biochem 2009;328:119-26.
20. Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009;11:119-29.
21. Eisert WG. Dipyridamole. In: Michelson AD, ed. Platelets, 1st ed. San Diego: Academic Press; 2002:803-15.
22. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005;111:633-42. (Pubitemid 40216492)
23. Iuliano L, Ghiselli A, Alessandri C, Bonavita MS, Violi F. Superoxide anion scavenging property of dipyridamole. Thromb Haemostasis 1989;61:149.
24. Iuliano L, Piccheri C, Coppola I, Pratico D, Micheletta F, Violi F. Fluorescence quenching of dipyridamole associated to peroxyl radical scavenging: a versatile probe to measure the chain breaking antioxidant activity of biomolecules. Biochim Biophys Acta 2000;1474:177-82. (Pubitemid 30162983)
25. Chakrabarti S, Vitseva O, Iyu D, Varghese S, Freedman JE. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J Pharmacol Exp Ther 2005;315:494-500. (Pubitemid 41500712)
26. Kusmic C, Picano E, Busceti CL, Petersen C, Barsacchi R. The antioxidant drug dipyridamole spares the vitamin E and thiols in red blood cells after oxidative stress. Cardiovasc Res 2000;47:510-4. (Pubitemid 30646072)
27. Kusmic C, Petersen C, Picano E, et al. Antioxidant effect of oral dipyridamole during cerebral hypoperfusion with human carotid endarterectomy. J Cardiovasc Pharmacol 2000;36:141-5. (Pubitemid 30659833)
28. Weyrich AS, Skalabrin EJ, Kraiss LW. Targeting the inflammatory response in secondary stroke prevention: a role for combining aspirin and extended-release dipyridamole. Am J Ther 2009;16:164-70.
29. Zhao L, Gray L, Leonardi-Bee J, Weaver CS, Heptinstall S, Bath PM. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 2006;17:100-4. (Pubitemid 43155616)
30. Melani A, Cipriani S, Corti F, Pedata F. Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. Ann N Y Acad Sci 2010;1207:89-96.
31. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
32. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001;103:2055-9. (Pubitemid 32373007)
33. Dibbs Z, Thornby J, White BG, et al. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 1999;33:1935-42.
34. Picano E, Abbracchio MP. European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation? Trends Pharmacol Sci 1998;19:14-6. (Pubitemid 28094087)